HOOK News and Press, HOOKIPA Pharma Inc.

2024-07-27 16:41:00 ET Market watchers, throughout the week, observed several Wall Street executives stepping up for new roles as part of leadership reshuffling.... Read the full article on Seeking Alpha For further details see: Executive reshuffles: PulteGroup, The Esté...

Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial Officer Company is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential...

A look at the top 10 most actives in the United States Longeveron Inc. (LGVN) rose 69.0% to $4.8499 on volume of 46,980,986 shares Virpax Pharmaceuticals Inc. (VRPX) rose 161.5% to $3.0333 on volume of 46,199,502 shares Maxeon Solar Technologies Ltd. (MAXN) fell 0.6% to $0.2464 on volume ...

2024-07-09 09:02:05 ET Hookipa Pharma Inc (HOOK) announced stock split at a ratio of 1-for-10 on 2024-07-10 ... Full story available on KlickAnalytics.com

2024-07-08 08:28:31 ET Read the full article on Seeking Alpha For further details see: Hookipa Pharma to execute 1-for-10 reverse stock split

NEW YORK and VIENNA, July 08, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that a 1-for-10 reverse stock split of its outstanding shares of...

Novel arenaviral therapeutic vaccine, developed in collaboration with Gilead Sciences, Inc. (Gilead), to be evaluated as a potential component of a curative regimen for human immunodeficiency virus (HIV) HOOKIPA achieves a $5 million non-dilutive milestone payment under its collabora...

Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumab In a subset of 17 evaluable patients with PD-L1 combined positive score (CPS) of 20 or higher, the Company’s selected registrati...

Company will present promising preliminary progression-free survival and overall survival data for patients with combined positive score (CPS) ≥20 Conference call on Tuesday, June 4, at 4:15 p.m. ET NEW YORK and VIENNA, May 30, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc....

2024-05-24 14:26:46 ET More on HOOKIPA Pharma Hookipa Pharma: 04/25/24 Update Should Be The First Of Several Positive Catalysts Hookipa to receive $10M from Roche as FDA clears cancer trial Seeking Alpha’s Quant Rating on HOOKIPA Pharma Historical earn...